Best Biotech Stocks Worth Watching – July 10th\n\nPosted by Defense World Staff on Jul 12th, 2025\n\nThermo Fisher Scientific, AbbVie, ProKidney, Bloom Energy, Danaher, Moderna, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop and commercialize medical therapies, drugs, diagnostics and other products derived from living organisms. They tend to exhibit high volatility and regulatory risk because new treatments must clear lengthy clinical trials and win government approvals. As a result, biotech stocks can offer substantial upside if a product succeeds—but they also carry elevated risk if research programs falter. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.\n\nThermo Fisher Scientific (TMO)\n\nThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.\n\nShares of TMO traded up $12.45 during mid-day trading on Thursday, hitting $432.33. 1,138,912 shares of the company’s stock were exchanged, compared to its average volume of 1,984,154. The firm has a fifty day moving average of $408.93 and a two-hundred day moving average of $477.89. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $627.88. The stock has a market cap of $163.20 billion, a price-to-earnings ratio of 25.34, a P/E/G ratio of 2.27 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.\n\nAbbVie (ABBV)\n\nAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.\n\nShares of NYSE ABBV traded up $4.09 during trading hours on Thursday, hitting $194.71. 2,057,772 shares of the stock were exchanged, compared to its average volume of 6,272,544. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. AbbVie has a one year low of $163.81 and a one year high of $218.66. The company’s 50 day moving average is $187.10 and its 200 day moving average is $188.78. The firm has a market capitalization of $343.94 billion, a P/E ratio of 82.90, a P/E/G ratio of 1.28 and a beta of 0.48.\n\nProKidney (PROK)\n\nProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.\n\nProKidney stock traded up $1.02 during mid-day trading on Thursday, reaching $5.36. The company had a trading volume of 55,422,205 shares, compared to its average volume of 3,132,873. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The company has a 50 day moving average of $0.89 and a 200-day moving average of $1.14. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -8.96 and a beta of 1.26.\n\nBloom Energy (BE)\n\nBloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.\n\nShares of NYSE:BE traded down $2.83 during midday trading on Thursday, reaching $25.88. 10,868,120 shares of the company’s stock were exchanged, compared to its average volume of 6,412,645. The company’s 50 day simple moving average is $20.65 and its two-hundred day simple moving average is $21.78. The firm has a market capitalization of $6.01 billion, a PE ratio of -517.50 and a beta of 3.22. Bloom Energy has a 12 month low of $9.02 and a 12 month high of $29.83. The company has a debt-to-equity ratio of 2.07, a quick ratio of 2.39 and a current ratio of 3.44.\n\nDanaher (DHR)\n\nDanaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.\n\nDHR traded up $5.66 during midday trading on Thursday, hitting $206.62. The company had a trading volume of 1,153,285 shares, compared to its average volume of 3,493,194. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market capitalization of $147.87 billion, a PE ratio of 40.06, a P/E/G ratio of 2.82 and a beta of 0.77. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The firm’s 50-day simple moving average is $195.77 and its 200-day simple moving average is $206.81.\n\nModerna (MRNA)\n\nModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.\n\nShares of NASDAQ MRNA traded up $1.07 during mid-day trading on Thursday, hitting $33.86. The company’s stock had a trading volume of 6,148,014 shares, compared to its average volume of 8,801,919. The stock has a market cap of $13.10 billion, a price-to-earnings ratio of -3.87 and a beta of 1.84. Moderna has a one year low of $23.15 and a one year high of $129.39. The company’s fifty day simple moving average is $26.95 and its 200-day simple moving average is $31.30.\n\nVertex Pharmaceuticals (VRTX)\n\nVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.\n\nVertex Pharmaceuticals stock traded up $1.92 during midday trading on Thursday, hitting $480.89. 253,574 shares of the stock were exchanged, compared to its average volume of 1,419,409. The company has a fifty day simple moving average of $448.74 and a two-hundred day simple moving average of $459.47. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a market capitalization of $123.49 billion, a PE ratio of -122.55 and a beta of 0.41. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01.

Best Biotech Stocks Worth Watching – July 10th

The article highlights seven biotech stocks to watch as of July 10, 2025, including Thermo Fisher Scientific, AbbVie, ProKidney, Bloom Energy, Danaher, Moderna, and Vertex Pharmaceuticals. These companies are analyzed for their financial performance, market capitalization, stock price movements, and clinical trial progress in the biotech sector.